BioCentury | Apr 26, 2019
Clinical News

Prothena sees potential path forward for amyloidosis candidate

...opportunities that could lead to further clinical investigation of amyloid light-chain (AL) amyloidosis candidate birtamimab (NEOD001...
...composite of all-cause mortality and cardiac hospitalizations (HR=0.84, 95% CI: 0.58, 1.2, p=0.33). Brian Moy, Assistant Editor NEOD001 Prothena...
BioCentury | Jan 31, 2019
Company News

Alexion takes option to acquire Caelum's amyloidosis program

...has changed since April 2018, when Prothena Corp. plc (NASDAQ:PRTA) discontinued development of its mAb NEOD001...
BioCentury | Jun 30, 2018
Finance

Hidden in the rough

...million, falling a tier. The CNS play discontinued development of amyloid light-chain (AL) amyloidosis candidate NEOD001...
...& Business Development AAVrh74.MHCK7.micro-Dystrophin Adcetris (Brand), SGN-35 (Compound #), brentuximab vedotin (Generic), Adcetris (Other) ALKS 5461 Intrathecal AVXS-101 MGL-3196, VIA-3196, 3196 NEOD001 NKTR-214 Opdivo...
BioCentury | Apr 27, 2018
Clinical News

Prothena discontinues AL amyloidosis candidate

...Prothena Corp. plc (NASDAQ:PRTA) discontinued development of amyloid light-chain (AL) amyloidosis candidate NEOD001. The company said...
...the Phase III VITAL trial following a futility analysis. The double-blind, international PRONTO trial evaluated NEOD001’s...
...of treatment in 129 previously treated AL amyloidosis patients with persistent cardiac dysfunction. Prothena said NEOD001...
BioCentury | Apr 23, 2018
Clinical News

Prothena plummets after amyloidosis failure

...69%) to $11.50 on Monday after it discontinued development of amyloid light-chain (AL) amyloidosis candidate NEOD001...
...shaved nearly $1 billion from Prothena's market cap, which dipped below $450 million. PRONTO evaluated NEOD001’s...
...of treatment in 129 previously treated AL amyloidosis patients with persistent cardiac dysfunction. Prothena said NEOD001...
BioCentury | May 17, 2017
Clinical News

Prothena completes enrollment in Phase IIb amyloidosis trial

...to previous treatment and have persistent cardiac dysfunction in the Phase IIb PRONTO trial of NEOD001...
...expects top-line data in 2Q18. The double-blind, placebo-controlled, international trial is evaluating 24 mg/kg IV NEOD001...
...mid-May. NEOD001 is a humanized mAb targeting amyloid. Prothena Corp. plc (NASDAQ:PRTA), Dublin, Ireland Product: NEOD001...
BioCentury | Mar 3, 2017
Financial News

Prothena raises $155.3M in follow-on

...quarter, the company expects to complete enrollment in the Phase III VITAL Amyloidosis Study evaluating NEOD001...
...the U.S. and EU to treat AL amyloidosis. Prothena shed $4.26 to $55.81 on Friday. Chris Lieu NEOD001 Prothena...
BioCentury | May 16, 2016
Product Development

Drug development gets personal

...CEO of Prothena Corp. plc, a late-stage clinical biotechnology company whose most advanced program is NEOD001...
BioCentury | Dec 7, 2015
Regulation

Action in amyloidosis

...Amyloidosis at the University of Pavia. Prothena Corp. plc has designed some studies of its NEOD001...
...biomarker as a primary endpoint and is running other studies measuring the biomarker alongside mortality. NEOD001...
...the design was based on feedback from EMA on the possibility for conditional approval of NEOD001...
BioCentury | Jun 8, 2015
Clinical News

NEOD001: Additional Phase I/II data

...dose of IV NEOD001 was 24 mg/kg given every 28 days. In 15 renal-evaluable patients, NEOD001...
...glomerular filtration rate (eGFR) worsening, plus 6 cases of stable disease. In 14 cardiac-evaluable patients, NEOD001...
...Data from an expansion portion of the trial in 29 patients are expected in 4Q15. NEOD001...
Items per page:
1 - 10 of 26